-+ 0.00%
-+ 0.00%
-+ 0.00%

aTyr Pharma wins Nasdaq extension to regain $1 minimum bid price compliance by Nov. 30

PUBT·06/08/2026 20:05:13
Listen to the news
aTyr Pharma wins Nasdaq extension to regain $1 minimum bid price compliance by Nov. 30
  • aTyr Pharma received a Nasdaq notice that its shares failed the $1 minimum bid-price rule under Listing Rule 5550(a)(2).
  • Nasdaq granted a second 180-day compliance period to Nov. 30, 2026; the stock must close at or above $1 for 10 straight sessions.
  • The company flagged a reverse stock split as a potential remedy if it cannot regain compliance through trading performance.
  • Failure to meet the requirement by Nov. 30, 2026 would trigger a delisting notice, with an option to appeal to a Nasdaq hearings panel.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001339970-26-000039), on June 08, 2026, and is solely responsible for the information contained therein.